PORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive OfficerPORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer

FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference

2026/01/08 17:15
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

PORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P. Morgan 2026 Healthcare Conference, taking place from January 12 – 15, 2026 in San Francisco, CA.

With more than a decade of expertise, FJBio has supported over 250 clients across Pharma, Biotech and Academia and contributed to more than 19 antibodies advancing to clinical stage development or the market. During his presentation, Dr. Lanthaler will address FJBio’s strategic positioning as a highly efficient, integrated partner. He will showcase the Company’s antibody discovery and development solutions, with a focus on innovation, data-driven platforms and scalable collaboration models across the biopharmaceutical ecosystem.

Presenter

Role

Date

Time

Venue

Dr. Werner Lanthaler

CEO, FJBio

Jan 13

09:00–09:25 AM

“Golden Gate” at THE WESTIN, 32nd floor

In addition to the CEO presentation, members of FJBio’s Senior Management and Business Development teams will attend the conference for strategic discussions with representatives of global pharmaceutical companies, biotechnology innovators and other industry partners throughout the event.

Dr. Werner Lanthaler, Chief Executive Officer of FairJourney Bio, commented: “I look forward to presenting FairJourney Bio’s unique platform for partnered pipeline building at this year’s J.P. Morgan 2026 Healthcare Conference. This conference brings together a highly curated group of global healthcare leaders and innovators and I appreciate the opportunity to engage in meaningful dialogue around the future of efficient, data-enabled antibody discovery and development.”

Participation as a presenting company at this conference is highly selective and considered a significant distinction, reflecting FJBio’s growing global recognition and relevance within the international life sciences community. The conference provides an important platform for FJBio to strengthen existing relationships, explore new strategic partnerships and further position the Company as a trusted global partner across the full value chain.

Contacts

FairJourney Biologics
Hinnerk Rohwedder

Head of Marketing & Communications

hrohwedder@fjbio.com

Zyme Communications

Lily Jeffery
Email: lily.jeffery@zymecommunications.com
Tel: +44 (0)7891 477 378

Market Opportunity
BIO Protocol Logo
BIO Protocol Price(BIO)
$0.01668
$0.01668$0.01668
-0.71%
USD
BIO Protocol (BIO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Trump’s Critical Warning: US Engages Iran’s New Regime in High-Stakes Talks, Threatens Strikes if Diplomacy Fails

Trump’s Critical Warning: US Engages Iran’s New Regime in High-Stakes Talks, Threatens Strikes if Diplomacy Fails

BitcoinWorld Trump’s Critical Warning: US Engages Iran’s New Regime in High-Stakes Talks, Threatens Strikes if Diplomacy Fails WASHINGTON, D.C. — March 15, 2025
Share
bitcoinworld2026/03/30 23:05
CME to launch Solana and XRP futures options on October 13, 2025

CME to launch Solana and XRP futures options on October 13, 2025

The post CME to launch Solana and XRP futures options on October 13, 2025 appeared on BitcoinEthereumNews.com. Key Takeaways CME Group will launch futures options for Solana (SOL) and XRP. The launch date is set for October 13, 2025. CME Group will launch futures options for Solana and XRP on October 13, 2025. The Chicago-based derivatives exchange will add the new crypto derivatives products to its existing digital asset offerings. The launch will provide institutional and retail traders with additional tools to hedge positions and speculate on price movements for both digital assets. The futures options will be based on CME’s existing Solana and XRP futures contracts. Trading will be conducted through CME Globex, the exchange’s electronic trading platform. Source: https://cryptobriefing.com/cme-solana-xrp-futures-options-launch-2025/
Share
BitcoinEthereumNews2025/09/18 01:07
If you put $1,000 in Intel at the start of 2025, here’s your return now

If you put $1,000 in Intel at the start of 2025, here’s your return now

The post If you put $1,000 in Intel at the start of 2025, here’s your return now appeared on BitcoinEthereumNews.com. Intel (NASDAQ: INTC) and Nvidia (NASDAQ: NVDA) announced a new partnership on Thursday, September 18, working on several generations of custom data center and computing chips designed to boost performance in hyperscale, enterprise, and consumer applications. As part of the collaboration, Nvidia, the undisputed leader of the semiconductor sector, will also invest $5 billion in Intel by purchasing its common stock at a price of $23.28 per share. Following the news, Intel stock jumped more than 30% in pre-market trading, while Nvidia saw a 3% uptick, a welcome change following weeks of shaky performance and controversies regarding its Chinese sales. Trading at $31.34 at the time of writing, INTC shares are up 54.99% year-to-date (YTD). INTC YTD stock price. Source: Google Accordingly, a $1,000 investment in the tech company at the start of the year would now be worth $1,549.90, giving you a return of $549.90. ‘The next era of computing’ The move follows a wave of fresh backing for the struggling Intel, including a nearly $9 billion U.S. government purchase of a 10% stake just weeks ago and a $2 billion investment from Japan’s SoftBank. As such, the deal has the potential to put Intel back into the game after years of trying to catch up not just with Nvidia but also AMD (NASDAQ: AMD) and Broadcom (NASDAQ: AVGO). “This historic collaboration tightly couples NVIDIA’s AI and accelerated computing stack with Intel’s CPUs and the vast x86 ecosystem — a fusion of two world-class platforms. Together, we will expand our ecosystems and lay the foundation for the next era of computing,” wrote Nvidia founder and chief executive officer (CEO), Jensen Huang.  However, the U.S. government’s direct involvement suggests that more is at stake than simply propping up Intel, as it likely reflects a broader concern about keeping America competitive…
Share
BitcoinEthereumNews2025/09/18 22:47